Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bepotastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 7/20 | 0.54 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MLNR | O43193 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bepotastine SCHEMBL30200949 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL29459 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL5151702 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL29440897 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL726880 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2803678 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2808049 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2806225 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2807641 | 0.95 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| SCHEMBL28391952 | 0.92 | BCHE (0.56) | BCHEDRD2NPC1MLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137367-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| EP-2144896-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008123701-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2008-10-16 | — | — | WO | disclosed |
| US-7282589-B2 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| US-20040220226-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. | 2004-11-04 | — | — | US | disclosed |
| US-6780877-B2 | ANTIHISTAMINIC ACTIVITY, ANTI-ALLERGIC ACTIVITY | UBE INDUSTRIES, LTD. (JP) | 2004-08-24 | — | — | US | disclosed |
| EP-0949260-B1 | ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-20020026054-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. | 2002-02-28 | — | — | US | disclosed |
| US-6307052-B1 | Acid-addition salts of optically active piperidine compound and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0949260-A1 | ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137367-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HRH1, NOTUM, HRH2 | HRH1 1/4885BCHE 41/4885DRD2 4080/4885 |
| US-20020026054-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | CMA1, HRH1, HRH2 | HRH1 2/4885BCHE 966/4885DRD2 1620/4885 |
| US-20040220226-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | DCTPP1, SSRP1, ITPA | HRH1 988/4885BCHE 3465/4885DRD2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.